Target type: biologicalprocess
The chemical reactions and pathways resulting in the formation of platelet activating factor, 1-O-alkyl-2-acetyl-sn-glycerol 3-phosphocholine, where alkyl = hexadecyl or octadecyl. Platelet activating factor is an inflammatory mediator released from a variety of cells in response to various stimuli. [ISBN:0198547684]
Platelet-activating factor (PAF) is a potent lipid mediator involved in a wide range of biological processes, including inflammation, allergic reactions, and blood clotting. Its biosynthesis is a complex process that involves multiple steps, starting with the conversion of membrane phospholipids to lysophosphatidylcholine (LPC). LPC is then acetylated by the enzyme lysophospholipase D (lysoPLD) to generate PAF, a phospholipid with a unique structure that includes an acetyl group at the sn-2 position of the glycerol backbone.
The synthesis of PAF typically occurs in response to stimuli such as bacterial endotoxins, complement activation, and tissue injury. Once synthesized, PAF acts as a signaling molecule, binding to its specific receptor (PAFR) on target cells, leading to a cascade of intracellular events, including activation of phospholipase C, protein kinase C, and calcium mobilization. These events ultimately trigger diverse cellular responses, such as platelet aggregation, smooth muscle contraction, vascular permeability, and leukocyte chemotaxis.
The biosynthesis of PAF is tightly regulated, and its production is carefully controlled to prevent excessive inflammation and other adverse effects. The enzymes involved in PAF synthesis are subject to regulation by various factors, including hormones, cytokines, and intracellular signaling pathways.
In addition to its role in inflammation and allergic reactions, PAF also plays a crucial role in the pathogenesis of various diseases, including asthma, sepsis, and stroke. The development of drugs that target the biosynthesis or signaling of PAF is an active area of research, aiming to provide novel therapeutic strategies for these conditions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cytosolic phospholipase A2 gamma | A cytosolic phospholipase A2 gamma that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UP65] | Homo sapiens (human) |
Cytosolic phospholipase A2 | A cytosolic phospholipase A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P47712] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
indomethacin | indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis. Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. | aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole | analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic; xenobiotic metabolite |
ici 204,219 | zafirlukast: a leukotriene D4 receptor antagonist | carbamate ester; indoles; N-sulfonylcarboxamide | anti-asthmatic agent; leukotriene antagonist |
arachidonic acid | arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid. icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14. | icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid | Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite |
arachidonyltrifluoromethane | AACOCF3 : A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group arachidonyltrifluoromethane: structure given in first source; inhibits 85-kDa phospholipase A2 | fatty acid derivative; ketone; olefinic compound; organofluorine compound | EC 3.1.1.4 (phospholipase A2) inhibitor |
amentoflavone | biflavonoid; hydroxyflavone; ring assembly | angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite | |
ochnaflavone | ochnaflavone : A biflavonoid with an ether linkage between the B-rings of the apigenin and luteolin subunits. It has been isolated from several members of the Ochnaceae plant family. ochnaflavone: from Lonicera japonica; structure given in first source | aromatic ether; biflavonoid; hydroxyflavone | anti-inflammatory agent; antiatherogenic agent; antibacterial agent; EC 3.1.1.4 (phospholipase A2) inhibitor; leukotriene antagonist; plant metabolite |
efipladib | efipladib: structure in first source | ||
methyl arachidonylfluorophosphonate | phosphonic ester | ||
pyrrophenone | pyrrophenone: structure in first source |